ReviewExpert opinion on drug delivery2018
Near-infrared biophotonics-based nanodrug release systems and their potential application for neuro-disorders.
Review in Expert opinion on drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Near-Infrared-Light-Driven Photochemistry and Photocatalysis: Mechanisms, Recent Applications, and Opportunities in Organic Synthesis and Biology.Angewandte Chemie (International ed. in English) · 2026Review
- Monoclonal Antibodies-Anchored Quantum Dots-Based Delivery Strategies for Glioblastoma Treatment: Challenges and Applications.Advanced pharmaceutical bulletin · 2025Review
- Nanomaterials engineered for photothermal therapy in neural tumors and neurodegenerative diseases: biomaterial design, clinical mechanisms and applications.Frontiers in bioengineering and biotechnology · 2025Review
- The Beneficial Role of Photobiomodulation in Neurodegenerative Diseases.Biomedicines · 2023Review
- Dendrimers: Advancements and Potential Applications in Cancer Diagnosis and Treatment-An Overview.Pharmaceutics · 2023Review
- Advances in photobiomodulation for cognitive improvement by near-infrared derived multiple strategies.Journal of translational medicine · 2023Review
- Bio-hybrid electronic and photonic devices.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- Engineering Spatiotemporal Control in Vascularized Tissues.Bioengineering (Basel, Switzerland) · 2022Review
- Visible-to-NIR-Light Activated Release: From Small Molecules to Nanomaterials.Chemical reviews · 2020Article
- Exploring near-infrared absorbing nanocarriers to overcome cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
introductionNear-infrared ray (NIR)-responsive 'smart' nanoagents allow spatial and temporal control over the drug delivery process, noninvasively, without affecting healthy tissues and therefore they possess high potential for on-demand, targeted drug/gene delivery. Various NIR-responsive drug/gene delivery techniques are under investigation for peripheral disorders (especially for cancer). Nonetheless, their potential not been extensively examined for brain biomedical application. AREAS COVERED: This review focuses on NIR-responsive characteristics of different NIR-nanobiophotonics-based nanoagents and associated drug delivery strategies. Together with their ongoing applications for peripheral drug delivery, we have highlighted the opportunities, challenges and possible solutions of NIR-nanobiophotonics for potential brain drug delivery. EXPERT OPINION: NIR-nanobiophotonics can be considered superior among all photo-controlled drug/gene delivery approaches. Future work should focus on coupling NIR with biocompatible nanocarriers to determine the physiological compatibility of this approach. Their applications should be extended beyond the peripheral body region to brain region. Transient or intermittent NIR exposure strategies may be more accommodating for brain physiological ambience in order to minimize or avoid the possible deleterious thermal effect. In addition, while most studies are centered around the first NIR spectral window (700-1000 nm), the potential of second (1100-1350 nm) and third (1600-1870 nm) windows must be explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.